Track topics on Twitter Track topics that are important to you
AEVIS VICTORIA SA / Key word(s): 9 Month figures
Fribourg, 29 October 2019
AEVIS VICTORIA SA: Strong revenue growth in the third quarter; Swiss Medical Network and Victoria-Jungfrau Collection continue to register organic growth
As at 30 September 2019, total revenues of AEVIS VICTORIA SA amounted to CHF 707.6 million (2018: CHF 469.1 million), including the gain on the sale of the Infracore stake of CHF 193.8 million. Net revenues (medical fees excluded) amounted to CHF 643.1 million, up by 56.4% compared to 2018 (CHF 411.3 million). Operating revenues increased by 9.5%, driven in particular by the strong performance in the hospital segment. Acquisitions excluded, organic growth reached 5.8% at group level and 6.3% for the hospital segment.
Victoria-Jungfrau Collection, the hospitality segment of AEVIS VICTORIA, generally performed well in a dynamic market environment. Total revenues reached CHF 49.9 million, compared to CHF 48.8 million last year, implying an organic growth of 2.3%. After the period under review, following the acquisition of 100% of Seiler & Partenaires Holding SA, Mont Cervin Palace and Hotel Monte Rosa were added to the luxury hotel portfolio. Hotel Eden au Lac, closed for complete renovation since October 2017, will reopen on 1 December 2019 under the brand name La Réserve Eden au Lac Zurich.
AEVIS favors investments as a reference shareholder in companies active in its focus sectors. As an active investor, AEVIS exerts significant influence on the strategies of the companies it holds shares in, leaving them with full responsibility for operational management. AEVIS will continue to collaborate with other market players in order to further develop and grow the activities of its participations, as it has been done for Infracore.
AEVIS wishes to offer its shareholders a combination of capital gains generated by value creation in its subsidiaries and a stable annual return. It is expected that the ordinary distribution will be substantially increased for the 2019 financial year.
For further information:
End of ad hoc announcement
Standard antiretroviral therapy (ART) consists of the combination of at least three antiretroviral (ARV) drugs to maximally suppress the HIV virus and stop the progression of HIV disease. Huge reductions have been seen in rates of death and suffering whe...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.